This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAbout AboutWhy PENBRAYA?Risks of Meningococcal DiseaseGaps in Vaccination CoverageDosing & Recommendations Effectiveness & Safety Effectiveness
& Safety ImmunogenicitySafety ProfileIn Your Practice In Your PracticeSimplified CombinationHow to Transition to PENBRAYAPreparing PENBRAYAResources ResourcesRequest a RepresentativeHealth Plan CoverageMaterialsVideos
Prescribing InformationIndicationsPatient SiteRequest a RepLoading
Substantial gaps in meningococcal vaccination leave the majority of older adolescents at risk1-9*It is important to protect older adolescents at age 16, especially as meningococcal disease risk rises†Meningococcal vaccination rates decline to suboptimal levels as adolescents age1‡
84.8% of HCPs agree that there is a significant gap in meningococcal vaccination coverage among teens13§
Disparities in meningococcal vaccination among adolescents persist, contributing to gaps in coverage14

Among 16-to 23-year-olds, the completion rate for the MenB vaccine series differs for individuals in the Medicaid database (44.7%) and individuals with commercial healthcare plans (56.7%), showing greater inequity in vaccination for patients covered by Medicaid.||

PENBRAYA, as a combination vaccine, may help close vaccination gaps against meningococcal serogroups A, B, C, W, and Y when your older adolescent patients need it 
the most1-3,15
Based on data in the CDC enhanced meningococcal surveillance reports from 2017 to 2022 for 16- to 23-year-olds. The number of cases for each serogroup were as follows: MenA=0; MenB=120; MenC=20; MenW=5; MenY=9; other/unknown=31; and non-groupable=49.4-9Risk rises and peaks in adolescents between ages 15 and 22.2Based on the 2022 National Immunization Survey of 13- to 17-year-olds in the United States, coverage rates among 17-year-olds for MenACWY was 90.7% for Dose 1 and 60.8% for Dose 2 (n=3019). For MenB coverage, 29.4% received Dose 1 and 11.9% received Dose 2 (n=3019). MenACWY ≥2 doses calculated only among adolescents aged 17 years at time of interview; does not include adolescents who received 1 MenACWY dose at age ≥16 years. The average MenACWY completion rate of ≥1 dose of MenACWY for 13- to 17-year-olds was 88.6% (n=16,043). MenB ≥1 dose calculated only among adolescents aged 17 years at time of interview, with vaccine administered based on individual clinical decision-making.1Based on a recent survey of HCPs (n=500).13Based on a retrospective cohort study using deidentified data from the IBM MarketScan Commercial Claims and Encounters Multi-State Medicaid databases between January 2017 through either November 2018 (Commercial) or September 2018 (Medicaid) and using a 15 month follow-up period for each group to assess vaccination completion. Inclusion criteria were ≥1 claim for a MenB vaccination during the identification period, 16 to 23 years of age on the index date, and continuous enrollment with medical and pharmacy benefits for ≥6 months before and ≥15 months after the index date. 156,080 Commercial and 57,082 Medicaid individuals met the study inclusion criteria.14CDC=Centers for Disease Control and Prevention; HCP=healthcare provider.Quick linksIcon of an information bubble Meningococcal Disease Risks Understand why fully vaccinating your adolescent patients is critical  See disease risks LoadingIcon of a hand with plus signs Why PENBRAYA?

PENBRAYA offers the broadest MenABCWY coverage in a single vaccine product

 Find out more LoadingIcon of a syringe Dosing and Recommendations

Learn about ACIP-recommended dosing for PENBRAYA

 See dosing Loadingcircle icon of a speech bubble representing meningococcal disease risks Meningococcal Disease Risks Understand why fully vaccinating your adolescent patients is critical  See disease risks Loadingcircle icon of a hand Why PENBRAYA?

PENBRAYA offers the broadest MenABCWY coverage in a single vaccine product

 Find out more Loadingcircle icon of a syringe representing dosing and recommendations Dosing and Recommendations

Learn about ACIP-recommended dosing for PENBRAYA

 See dosing Loading

References: 1. Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13–17 years—National Immunization Survey–Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912-919. 2. Meningococcal disease: surveillance data tables. Centers for Disease Control and Prevention. Last reviewed July 10, 2023. Accessed April 28, 2023. https://www.cdc.gov/meningococcal/surveillance/surveillance-data.html 3. Collins JP, Crowe JS, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices ― United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345-350. 4. Enhanced meningococcal disease surveillance report, 2017. Centers for Disease Control and Prevention. Accessed June 27, 2024. https://stacks.cdc.gov/view/cdc/75419 5. Enhanced meningococcal disease surveillance report, 2018. Centers for Disease Control and Prevention. Accessed June 27, 2024. https://stacks.cdc.gov/view/cdc/111348 6. Enhanced meningococcal disease surveillance report, 2019. Centers for Disease Control and Prevention. Accessed October 27, 2023. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2019.pdf 7. Enhanced meningococcal disease surveillance report, 2020. Centers for Disease Control and Prevention. Accessed October 27, 2023. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2020.pdf 8. Enhanced meningococcal disease surveillance report, 2021. Centers for Disease Control and Prevention. Accessed October 27, 2023. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2021.pdf 9. Enhanced meningococcal disease surveillance report, 2022. Centers for Disease Control and Prevention. Accessed May 6, 2024. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2022-508.pdf 10. Vaccines and preventable diseases: meningococcal vaccination. Centers for Disease Control and Prevention. Last reviewed November 20, 2023. Accessed January 22, 2024. https://www.cdc.gov/vaccines/vpd/mening/index.html 11. Meningitis. World Health Organization. Published 2023. Accessed April 27, 2023. https://www.who.int/health-topics/meningitis#tab=tab_2 12. Meningococcal disease: diagnosis, treatment, and complications. Centers for Disease Control and Prevention. Last reviewed February 7, 2022. Accessed March 21, 2023. https://www.cdc.gov/meningococcal/about/diagnosis-treatment.html 13. Data on file. IPSOS HCP survey. Pfizer Inc., New York, NY. 14. Packnett ER, Zimmerman NM, Kim G, et al. A real-world claims data analysis of meningococcal serogroup B vaccine series completion and potential missed opportunities in the United States. Pediatr Infect Dis J. 2022;41(4):e158-e165. 15. PENBRAYA [prescribing information]. New York, NY: Pfizer Inc.; 2023.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PBI-USA-0339
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age 
Important Safety Information
  • Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis group B, even if they develop antibodies following vaccination with TRUMENBA
  • Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
  • Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks 
  • For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
  • For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals
     
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age